Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Gut. 2022 Sep;71(9):1697-1723. doi: 10.1136/gutjnl-2022-327737. Epub 2022 Jul 7.
Functional dyspepsia (FD) is a common disorder of gut-brain interaction, affecting approximately 7% of individuals in the community, with most patients managed in primary care. The last British Society of Gastroenterology (BSG) guideline for the management of dyspepsia was published in 1996. In the interim, substantial advances have been made in understanding the complex pathophysiology of FD, and there has been a considerable amount of new evidence published concerning its diagnosis and classification, with the advent of the Rome IV criteria, and management. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based diagnosis and treatment of patients. The approach to investigating the patient presenting with dyspepsia is discussed, and efficacy of drugs in FD summarised based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of pairwise and network meta-analyses. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system. These provide both the strength of the recommendations and the overall quality of evidence. Finally, in this guideline, we consider novel treatments that are in development, as well as highlighting areas of unmet need and priorities for future research.
功能性消化不良(FD)是一种常见的胃肠脑相互作用紊乱,影响社区中约 7%的个体,大多数患者在初级保健中得到管理。英国胃肠病学会(BSG)最后一次发布消化不良管理指南是在 1996 年。在此期间,人们对 FD 的复杂病理生理学有了实质性的认识进展,并且随着罗马 IV 标准的出现,关于其诊断和分类的大量新证据已经发表,管理也随之而来。本指南由 BSG 委托编写,主要目的是审查和总结当前证据,为临床实践提供信息和指导,为基于证据的消化不良患者诊断和治疗提供实用框架。本文讨论了对消化不良患者的检查方法,并根据从医学文献全面搜索中获得的证据,对 FD 药物的疗效进行了总结,这些证据用于更新一系列成对和网络荟萃分析。根据推荐评估、制定和评估系统,提出了具体建议。这些建议既提供了建议的强度,也提供了证据的总体质量。最后,在本指南中,我们考虑了正在开发中的新型治疗方法,以及突出了未满足的需求领域和未来研究的优先事项。